Icares Medicus Inc (6612) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Icares Medicus Inc (6612) has a cash flow conversion efficiency ratio of -0.002x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-4.61 Million ≈ $-145.30K USD) by net assets (NT$1.97 Billion ≈ $62.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Icares Medicus Inc (6612) net asset quality to measure how much of total assets are equity-financed.
Icares Medicus Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Icares Medicus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Icares Medicus Inc to evaluate the quality of earnings relative to operating cash generation.
Icares Medicus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icares Medicus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kamdhenu Limited
NSE:KAMDHENU
|
0.035x |
|
MegaStudy Co. Ltd
KQ:072870
|
0.031x |
|
Yen Sun Technology
TWO:6275
|
0.086x |
|
Aluko Co Ltd
KO:001780
|
0.068x |
|
Curo Holdings Co. Ltd
KQ:051780
|
-0.068x |
|
WTK Holdings Bhd
KLSE:4243
|
0.074x |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
0.070x |
|
Maywood Acquisition Corp. 2 Class A Ordinary Share
NASDAQ:MYX
|
-1.341x |
Annual Cash Flow Conversion Efficiency for Icares Medicus Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Icares Medicus Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Icares Medicus Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.97 Billion ≈ $62.01 Million |
NT$-58.83 Million ≈ $-1.85 Million |
-0.030x | -8.59% |
| 2024-12-31 | NT$1.76 Billion ≈ $55.54 Million |
NT$-48.52 Million ≈ $-1.53 Million |
-0.028x | -78.13% |
| 2023-12-31 | NT$1.67 Billion ≈ $52.58 Million |
NT$-25.79 Million ≈ $-812.43K |
-0.015x | -111.24% |
| 2022-12-31 | NT$937.76 Million ≈ $29.54 Million |
NT$128.92 Million ≈ $4.06 Million |
0.137x | +192.61% |
| 2021-12-31 | NT$820.90 Million ≈ $25.86 Million |
NT$38.57 Million ≈ $1.22 Million |
0.047x | -53.76% |
| 2020-12-31 | NT$702.42 Million ≈ $22.13 Million |
NT$71.37 Million ≈ $2.25 Million |
0.102x | -25.26% |
| 2019-12-31 | NT$653.04 Million ≈ $20.57 Million |
NT$88.78 Million ≈ $2.80 Million |
0.136x | +22.87% |
| 2018-12-31 | NT$571.42 Million ≈ $18.00 Million |
NT$63.22 Million ≈ $1.99 Million |
0.111x | -18.11% |
| 2017-12-31 | NT$336.57 Million ≈ $10.60 Million |
NT$45.47 Million ≈ $1.43 Million |
0.135x | -- |
About Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataract… Read more